September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
INTRAVITREAL BEVACIZUMAB PLUS BRINZOLAMIDE VERSUS INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY: PILOT STUDY.
Author Affiliations & Notes
  • Jesús Ramón Alvarez-Félix
    CIDOCS, Universidad Autonoma de Sinaloa, Culiacan, Sinaloa, Mexico
  • PIMENTEL KARLA
    CIDOCS, Universidad Autonoma de Sinaloa, Culiacan, Sinaloa, Mexico
  • SILVIA PAZ
    CIDOCS, Universidad Autonoma de Sinaloa, Culiacan, Sinaloa, Mexico
  • YOLANDA CHAVEZ ROMERO
    CIDOCS, Universidad Autonoma de Sinaloa, Culiacan, Sinaloa, Mexico
  • ABEL RAMON
    CIDOCS, Universidad Autonoma de Sinaloa, Culiacan, Sinaloa, Mexico
  • David Magana
    CIDOCS, Universidad Autonoma de Sinaloa, Culiacan, Sinaloa, Mexico
  • Sergio Sital-Gastelum
    CIDOCS, Universidad Autonoma de Sinaloa, Culiacan, Sinaloa, Mexico
  • Efrain Romo-Garcia
    CIDOCS, Universidad Autonoma de Sinaloa, Culiacan, Sinaloa, Mexico
  • Footnotes
    Commercial Relationships   Jesús Ramón Alvarez-Félix, None; PIMENTEL KARLA, None; SILVIA PAZ, None; YOLANDA CHAVEZ ROMERO, None; ABEL RAMON, None; David Magana, None; Sergio Sital-Gastelum, None; Efrain Romo-Garcia, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2037. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jesús Ramón Alvarez-Félix, PIMENTEL KARLA, SILVIA PAZ, YOLANDA CHAVEZ ROMERO, ABEL RAMON, David Magana, Sergio Sital-Gastelum, Efrain Romo-Garcia; INTRAVITREAL BEVACIZUMAB PLUS BRINZOLAMIDE VERSUS INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY: PILOT STUDY.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2037.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Controversy exists regarding to achieve a faster and better outcome after a central serous chorioretinopathy (CSC). We perform a pilot study to compare the efficacy of intravitreal bevacizumab plus brinzolamide versus intravitreal bevacizumab for CSC.

Methods : Patients diagnosed with CSC were recruited from July to October 2015, of any age and sex, without prior treatment or other ocular pathology. They were divided randomly into 3 groups: group 1 = intravitreal bevacizumab, group 2 = topical brinzolamide bid for 2 weeks followed by intravitreal bevacizumab, group 3 = brinzolamide bid for 4 weeks; we analyze the following variables: sex, age, initial BCVA and the primary outcomes variables: final best corrected visual acuity (BCVA, expressed in LogMAR) and central foveal thickness (CFT, in µm) measured by SD-OCT at baseline and at 4 weeks.

Results : We analyze 35 patients using ANOVA for 3 treatment groups, we found 77.1% were male and 51.4% had involvement of the right eye. Group 1 n=12 patients, group 2 n=12 patients, group 3 n=11. The age range was from 22 to 65 years, with an average age of 38+11.3. An initial average of uncorrected visual acuity (LogMAR) of 0.329 in group 1, 0.409 in group 2, 0.410 in group 3 (p = 0.794). We found a statistically significant difference in group 1 (Bevacizumab) between the initial and final BCVA (LogMAR) with an improvement in the average of -0.100 (p = 0.002), the final CFT average obtained were: group 1= 286.7±57.4, group 2= 296.1±61.9, group 3= 283.3±30.8; this results were similar in 3 groups and statistically different from initial CFT (p=0.000, p=0.000 and p=0.008 respectively).

Conclusions : We found statistically significant difference in the final BCVA in the bevacizumab group, towards a better final BCVA in group 1, however 3 groups had good final BCVA and CFT.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×